FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915432012> ?p ?o ?g. }

• W2915432012 abstract "There is a compelling need to find effective treatments for metastatic prostate cancer. The ideal treatment would only target metastatic lesion while sparing normal tissue. Down-regulation of specific pathways using small interfering RNA (siRNA) provides unique opportunities to target cancer cells selectively while sparing normal tissue. Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein that has abundant expression on the surface of prostate carcinomas, particularly in androgen-independent, advanced and metastatic disease [1-2]. We are developing prostate specific membrane antigen (PSMA) targeted nanoplexes carrying multimodality imaging reporters together with small interfering RNA (siRNA) and a prodrug enzyme, bacterial cytosine deaminase (bCD), for theranostic imaging of metastatic prostate cancer. We have incorporated a low molecular weight PSMA binding agent in the nanoplex to target the nanoplex to prostate cancer cells [3]. Since choline kinase (Chk) is significantly upregulated in aggressive cancer cells we have used siRNA against Chk in the nanoplex. Our prototype nanoplexes are synthesized by conjugating: (i) a low molecular weight urea-based PSMA targeting moiety (2-(3-[1-carboxy-5-[7-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-heptanoylamino]-pentyl]-ureido)-pentanedioic acid, (ii) the prodrug-activating enzyme bCD that converts nontoxic 5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU), (iii) the multimodal imaging reporter carrier poly-L-lysine (PLL) that carries [111In]DOTA for SPECT or [Gd3+]DOTA for MR, and a near-infrared fluorescent probe Cy5.5 for optical imaging, and (iv) the siRNA delivery vector: PEI (polyethyleneimine)-PEG (polythethyeneglycol) co-grafted-polymer. Imaging studies with PSMA targeted nanoplexes were performed with PC-3 human prostate cancer xenografts genetically engineered to overexpress PSMA (PC-3 PIP) in SCID mice. Non PSMA expressing PC-3 xenografts (PC-3 FLU) were used as controls. The addition of a low molecular weight PSMA targeting moiety allowed specific targeting of the nanoplex to PSMA expressing prostate cancer cells in vivo, which was further established with blocking studies. Initial studies established the ability of the nanoplex to effectively downregulate Chk and total choline and convert the nontoxic prodrug 5-FC to 5-FU. The strategies developed here can be extended, in the future, to down-regulate multi-drug resistance pathways, or repair enzymes to increase the efficiency of chemo- or radiation therapy. 1. Schulke, N., et al., Proc Natl Acad Sci U S A, 2003; 2. Huang, X., et al., Prostate, 2004; 3. Mease, R., et al., Clin. Cancer Res., 2008. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3629. doi:10.1158/1538-7445.AM2011-3629" @default.
• W2915432012 created "2019-03-02" @default.
• W2915432012 creator A5009487218 @default.
• W2915432012 creator A5009590736 @default.
• W2915432012 creator A5013167713 @default.
• W2915432012 creator A5014794283 @default.
• W2915432012 creator A5026291909 @default.
• W2915432012 creator A5037791204 @default.
• W2915432012 creator A5046935079 @default.
• W2915432012 creator A5049127734 @default.
• W2915432012 creator A5049568817 @default.
• W2915432012 creator A5070280228 @default.
• W2915432012 date "2011-04-15" @default.
• W2915432012 modified "2023-09-25" @default.
• W2915432012 title "Abstract 3629: Theranostic imaging of metastatic prostate cancer" @default.
• W2915432012 doi "https://doi.org/10.1158/1538-7445.am2011-3629" @default.
• W2915432012 hasPublicationYear "2011" @default.
• W2915432012 type Work @default.
• W2915432012 sameAs 2915432012 @default.
• W2915432012 citedByCount "0" @default.
• W2915432012 crossrefType "proceedings-article" @default.
• W2915432012 hasAuthorship W2915432012A5009487218 @default.
• W2915432012 hasAuthorship W2915432012A5009590736 @default.
• W2915432012 hasAuthorship W2915432012A5013167713 @default.
• W2915432012 hasAuthorship W2915432012A5014794283 @default.
• W2915432012 hasAuthorship W2915432012A5026291909 @default.
• W2915432012 hasAuthorship W2915432012A5037791204 @default.
• W2915432012 hasAuthorship W2915432012A5046935079 @default.
• W2915432012 hasAuthorship W2915432012A5049127734 @default.
• W2915432012 hasAuthorship W2915432012A5049568817 @default.
• W2915432012 hasAuthorship W2915432012A5070280228 @default.
• W2915432012 hasConcept C104317684 @default.
• W2915432012 hasConcept C108215921 @default.
• W2915432012 hasConcept C111599444 @default.
• W2915432012 hasConcept C121608353 @default.
• W2915432012 hasConcept C126322002 @default.
• W2915432012 hasConcept C150903083 @default.
• W2915432012 hasConcept C185592680 @default.
• W2915432012 hasConcept C20417620 @default.
• W2915432012 hasConcept C207001950 @default.
• W2915432012 hasConcept C22615655 @default.
• W2915432012 hasConcept C2776235491 @default.
• W2915432012 hasConcept C2777748644 @default.
• W2915432012 hasConcept C2778172261 @default.
• W2915432012 hasConcept C2780192828 @default.
• W2915432012 hasConcept C502942594 @default.
• W2915432012 hasConcept C54009773 @default.
• W2915432012 hasConcept C55493867 @default.
• W2915432012 hasConcept C71924100 @default.
• W2915432012 hasConcept C86803240 @default.
• W2915432012 hasConceptScore W2915432012C104317684 @default.
• W2915432012 hasConceptScore W2915432012C108215921 @default.
• W2915432012 hasConceptScore W2915432012C111599444 @default.
• W2915432012 hasConceptScore W2915432012C121608353 @default.
• W2915432012 hasConceptScore W2915432012C126322002 @default.
• W2915432012 hasConceptScore W2915432012C150903083 @default.
• W2915432012 hasConceptScore W2915432012C185592680 @default.
• W2915432012 hasConceptScore W2915432012C20417620 @default.
• W2915432012 hasConceptScore W2915432012C207001950 @default.
• W2915432012 hasConceptScore W2915432012C22615655 @default.
• W2915432012 hasConceptScore W2915432012C2776235491 @default.
• W2915432012 hasConceptScore W2915432012C2777748644 @default.
• W2915432012 hasConceptScore W2915432012C2778172261 @default.
• W2915432012 hasConceptScore W2915432012C2780192828 @default.
• W2915432012 hasConceptScore W2915432012C502942594 @default.
• W2915432012 hasConceptScore W2915432012C54009773 @default.
• W2915432012 hasConceptScore W2915432012C55493867 @default.
• W2915432012 hasConceptScore W2915432012C71924100 @default.
• W2915432012 hasConceptScore W2915432012C86803240 @default.
• W2915432012 hasLocation W29154320121 @default.
• W2915432012 hasOpenAccess W2915432012 @default.
• W2915432012 hasPrimaryLocation W29154320121 @default.
• W2915432012 hasRelatedWork W1617274189 @default.
• W2915432012 hasRelatedWork W1973877782 @default.
• W2915432012 hasRelatedWork W2025025126 @default.
• W2915432012 hasRelatedWork W2030889647 @default.
• W2915432012 hasRelatedWork W2041972351 @default.
• W2915432012 hasRelatedWork W2055204109 @default.
• W2915432012 hasRelatedWork W2166961017 @default.
• W2915432012 hasRelatedWork W2324631901 @default.
• W2915432012 hasRelatedWork W2466093998 @default.
• W2915432012 hasRelatedWork W2494093282 @default.
• W2915432012 hasRelatedWork W2528546669 @default.
• W2915432012 hasRelatedWork W2735627255 @default.
• W2915432012 hasRelatedWork W2802632873 @default.
• W2915432012 hasRelatedWork W2911635447 @default.
• W2915432012 hasRelatedWork W2918517907 @default.
• W2915432012 hasRelatedWork W2949144514 @default.
• W2915432012 hasRelatedWork W3112372269 @default.
• W2915432012 hasRelatedWork W3113765337 @default.
• W2915432012 hasRelatedWork W3184675556 @default.
• W2915432012 hasRelatedWork W256211433 @default.
• W2915432012 isParatext "false" @default.
• W2915432012 isRetracted "false" @default.
• W2915432012 magId "2915432012" @default.
• W2915432012 workType "article" @default.